(Q44816551)

English

The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma

scientific article published in April 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

1 reference

based on heuristic

inferred from title

Mucin 16, cell surface associated

1 reference

based on heuristic

inferred from title

Angiolo Gadducci

1

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

author name string

Stefania Cosio

2

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Antonio Fanucchi

3

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Simona Negri

4

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Renza Cristofani

5

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Andrea Riccardo Genazzani

6

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

language of work or name

0 references

publication date

1 April 2004

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

93

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

131-136

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

The CA 125 tumour-associated antigen: a review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.043

7 January 2021

Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.043

7 January 2021

Serum half-life of the tumor marker CA 125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.043

7 January 2021

Serum CA125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.043

7 January 2021

Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.043

7 January 2021

CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.043

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.043

7 January 2021

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.043

7 January 2021

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.043

7 January 2021

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.043

7 January 2021

Up date in the management of advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.043

7 January 2021

A new standard of care for treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.043

7 January 2021

First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: a phase I/II study of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.043

7 January 2021

First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.043

7 January 2021

CA 125: a valid marker in ovarian carcinoma patients treated with paclitaxel?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.043

7 January 2021

Effects of paclitaxel on CA-125 serum levels in ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.043

7 January 2021

Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.043

7 January 2021

The CA125 regression rate to predict overall survival differ between paclitaxel-containing regimen and nonpaclitaxel regimen in patients with advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.043

7 January 2021

Modulation of tumour marker CA-125 expression in cultured ovarian carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.043

7 January 2021

Effect of paclitaxel (Taxol) on CA 125 expression and release by ovarian cancer cell lines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.043

7 January 2021

CA 125 regression: a model for epithelial ovarian cancer response.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.043

7 January 2021

Identifiers

10.1016/J.YGYNO.2003.12.043

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44816551&oldid=2167619133"